Molecular Tumor Boards: A Consensus Statement From the International Association for the Study of Lung Cancer.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Aldea Mihaela, Rotow Julia K, Arcila Maria, Hatton Matthew, Sholl Lynette, Rolfo Christian, Tagliamento Marco, Radonic Teodora, Schalper Kurt A, Subbiah Vivek, Malapelle Umberto, Roden Anja C, Manochakian Rami, Tsao Ming-Sound, Linardou Helena, Hui Rina, Novello Silvia, Greystoke Alastair, Saqi Anjali, Lantuejoul Sylvie, Hwang David M, Nevins Kelly, Wynes Murry, Waqar Saiama, Han Yuchen, Yatabe Yasushi, Chang Wei-Chin, Hayashi Takuo, Kim Tae-Jung, Hofman Paul, Tavora Fabio, Hirsch Fred R, Denninghoff Valeria, Leighl Natasha B, Drilon Alexander, Cooper Wendy A, Dacic Sanja, Mohindra Pranshu, Pavlakis Nick, Lopez-Rios Fernando
Аннотация
OBJECTIVE: To establish recommendations for MTB implementation, outline practical frameworks for their operation, and address disparities in expertise and resources between new and established MTBs.
DESIGN: A modified Delphi method involved 37 international experts in three survey rounds and online meetings, with consensus defined as more than or equal to 75% agreement.
RESULTS: The panel identified a molecular biologist or pathologist with expertise in molecular diagnostics and tumor-specific medical oncologists as indispensable MTB members. Case selection should reflect institutional expertise and volume, with newer MTBs reviewing less selected cases to gain experience. Regular meetings are advised to avoid delays beyond 14 days from result availability to discussion. Reporting should be standardized to include clinicopathologic data (tumor characteristics, treatment history), biomarker findings (testing results, sample details), and recommendations (treatment, retesting, genetic counseling). Treatment options should be ranked by the level of evidence for actionability and may include options not available locally. Performance evaluation should consider changes in patient management based on MTB input and matched therapy rates.
CONCLUSIONS: These MTB consensus recommendations are applicable across tumor types, despite being developed by lung cancer and molecular specialists and initiated by the International Association for the Study of Lung Cancer. They provide a structured framework for MTB implementation, report standardization, case selection, and quality assessment, aiming to standardize practice and address gaps in expertise for personalized cancer care.